ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Pheon’s lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. Pheon is backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies (RCT). Pheon has a world class, proven leadership team that brings together the best of ADC engineering, clinical and managerial expertise and track record.
For further information, visit www.pheontx.com
Location: United Kingdom, England, London
Investors 3
| Date | Name | Website |
| 06.10.2022 | Brandon Ca... | brandoncap... |
| - | Forbion | forbion.co... |
| 03.10.2022 | Atlas Vent... | atlasventu... |
Mentions in press and media 5
| Date | Title | Description | Source |
| 09.10.2023 | Brandon Capital Joins AstronauTx’ £48 million ($61 million) ... | Brandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatme... | brandoncap... |
| 28.09.2022 | Pheon Therapeutics Launches with $68M Series A | BOSTON, MA, Pheon Therapeutics (Pheon), an Antibody-Drug Conjugate (ADC) specialist, launched foll... | vcnewsdail... |
| 28.09.2022 | Brandon Capital co-Leads USD68M Series A Financing of London... | Melbourne, Australia and London UK, 28 September 2022 –Brandon Capital, Australasia’s leading life s... | brandoncap... |
| 28.09.2022 | Pheon Therapeutics Raises $68M in Series A Financing | Pheon Therapeutics, a London, UK-based Antibody Drug Conjugate company developing a pipeline of mono... | finsmes.co... |
| - | Pheon Therapeutics | “Pheon Therapeutics – Developing next generation ADCs for a wide range of hard-to-treat cancers”... | fastfounde... |